Impact of prognostically adverse mutations on IPSS risk groups. (A-C) Overall survival of patients in the low-, intermediate-1, and intermediate-2 IPSS risk groups, respectively, stratified by the presence and absence of mutations in TP53, EZH2, ETV6, RUNX1, or ASXL1. The overall survival curve for patients in the next-highest IPSS risk group is included for comparison. Patients with one or more of these mutation have a survival risk comparable to those in the next highest IPSS risk group. Used with permission from Bejar et al.²⁸